The Effect of Long-Term Low-Dose Atropine on Refractive Progression in Myopic Australian School Children

Myopia will affect half the global population by 2050 and is a leading cause of vision impairment. High-dose atropine slows myopia progression but with undesirable side-effects. Low-dose atropine is an alternative. We report the effects of 0.01% or 0.005% atropine eye drops on myopia progression in 13 Australian children aged between 2 and 18 years and observed for 2 years without and up to 5 years (mean 2.8 years) with treatment. Prior to treatment, myopia progression was either 'slow' (more positive than -0.5 D/year; mean -0.19 D/year) or 'fast' (more negative than -0.5 D/year; mean -1.01 D/year). Atropine reduced myopic progression rates (slow: -0.07 D/year, fast: -0.25 D/year, combined: before: -0.74, during: -0.18 D/year, p = 0.03). Rebound occurred in 3/4 eyes that ceased atropine. Atropine halved axial growth in the 'Slow' group relative to an age-matched model of untreated myopes (0.098 vs. 0.196 mm/year, p < 0.001) but was double that in emmetropes (0.051 mm/year, p < 0.01). Atropine did not slow axial growth in 'fast' progressors compared to the age-matched untreated myope model (0.265 vs. 0.245 mm/year, p = 0.754, Power = 0.8). Adverse effects (69% of patients) included dilated pupils (6/13) more common in children with blue eyes (5/7, p = 0.04). Low-dose atropine could not remove initial myopia offsets suggesting treatment should commence in at-risk children as young as possible.